Spring shoppers pick up discount deals
This article was originally published in Scrip
The announcements this week of the acquisitions of Cambridge UK-based Astex Therapeutics by SuperGen, and Inspire Pharmaceuticals by Merck might be heralded as the long-awaited thaw in the sector, another symptom of which has been the lack of initial public offerings. Both transactions however, together with the US IPO of Tranzyme however, more closely represent a continuation of the distinctly chilly backdrop for the life science space.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.